Sugi Predict

Sugi Predict / Targets / EPS15

EPS15

Epidermal growth factor receptor substrate 15 · P42566 · EPS15 on Sugi Atlas →

267 patent compounds predicted against EPS15, 203 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29411880 SCHEMBL29411880 0.61 1/20
SCHEMBL13254563 SCHEMBL13254563 0.61 1/20
SCHEMBL27401363 SCHEMBL27401363 0.58 1/20
SCHEMBL13254567 SCHEMBL13254567 0.58 1/20
SCHEMBL29666534 SCHEMBL29666534 0.55 1/20
SCHEMBL29885541 SCHEMBL29885541 0.54 1/20
SCHEMBL29370036 SCHEMBL29370036 0.54 1/20
Murepavadin Murepavadin (SCHEMBL29458093) 0.54 1/20
SCHEMBL30524414 SCHEMBL30524414 0.54 1/20
SCHEMBL23110146 SCHEMBL23110146 0.53 1/20
SCHEMBL29362264 SCHEMBL29362264 0.53 1/20
SCHEMBL1373163 SCHEMBL1373163 0.53 1/20
SCHEMBL23110202 SCHEMBL23110202 0.52 1/20
SCHEMBL27332332 SCHEMBL27332332 0.52 1/20
Cyclomontanin A Cyclomontanin A (SCHEMBL30139338) 0.51 1/20
SCHEMBL30787065 SCHEMBL30787065 0.51 1/20
SCHEMBL27401457 SCHEMBL27401457 0.51 1/20
SCHEMBL30577898 SCHEMBL30577898 0.51 1/20
SCHEMBL30577899 SCHEMBL30577899 0.51 1/20
SCHEMBL30577900 SCHEMBL30577900 0.51 1/20

Clinical trials — most relevant to EPS15 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer PHASE2COMPLETED
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene PHASE2UNKNOWN
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer PHASE2COMPLETED
EGF Ointment for Erlotinib Skin Lesion PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC PHASE2NOT_YET_RECRUITING
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer PHASE2COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Anti-EGFR Immunoliposomes in Solid Tumors PHASE1COMPLETED
Bevacizumab in Multiple Phase I Combinations PHASE1COMPLETED
Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer PHASE1WITHDRAWN
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. EARLY_PHASE1RECRUITING
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery EARLY_PHASE1COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth nanCOMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
IRS Proteins and Trastuzumab Resistance nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC nanUNKNOWN
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment nanUNKNOWN
Rectal Cancer Consortium nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EPS15 binder may also engage these)

ProteinNameSimilarity
P42567 — 1.000 P42567 →
Q60902 — 0.985 Q60902 →
Q6ZWJ1 — 0.982 Q6ZWJ1 →
Q9UBC2 — 0.981 Q9UBC2 →
Q923U0 — 0.981 Q923U0 →
Q09YG9 — 0.980 Q09YG9 →
Q00PJ1 — 0.979 Q00PJ1 →
A0M8T5 — 0.979 A0M8T5 →
Q2IBE6 — 0.979 Q2IBE6 →
Q2IBA2 — 0.978 Q2IBA2 →
F1LM81 — 0.978 F1LM81 →
Q5T1M5 — 0.978 Q5T1M5 →
Q09YJ3 — 0.978 Q09YJ3 →
Q8K2L8 — 0.977 Q8K2L8 →
Q2IBF8 — 0.977 Q2IBF8 →
Q9ULJ8 — 0.977 Q9ULJ8 →
Q07E15 — 0.977 Q07E15 →
Q09YK4 — 0.977 Q09YK4 →
RBM26 RNA-binding protein 26 0.977 landscape →
Q4V8Y7 — 0.977 Q4V8Y7 →
Q6NZN0 — 0.977 Q6NZN0 →
Q5R4U3 — 0.976 Q5R4U3 →
Q8BMI3 — 0.976 Q8BMI3 →
Q62415 — 0.976 Q62415 →
Q96D71 — 0.976 Q96D71 →
Q13625 — 0.976 Q13625 →
Q8WZ74 — 0.976 Q8WZ74 →
Q9HAU0 — 0.976 Q9HAU0 →
E1BTG2 — 0.976 E1BTG2 →
Q9WV89 — 0.976 Q9WV89 →